ArticleFrontiers in public health2026
Herpes zoster burden in a private healthcare setting of Argentina.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Herpes zoster (HZ) is a frequent condition that can lead to debilitating pain, with complications that may persist for months. The most frequent complication is postherpetic neuralgia (PHN), but ocular, nervous, and dermatological complications are also common. While the incidence of HZ increases with age, few studies have assessed its burden in Latin America, particularly in Argentina. Methods: We conducted a retrospective cohort study using the electronic health records of the Italian Hospital of Buenos Aires (HIBA) Health Plan from 2010 to 2022. We included members of the HIBA Health Insurance Plan aged over 18 years with HZ in the analysis. We calculated the incidence of HZ and its complications in the general population. Results: During the study period, an average of 138,977 members were followed up yearly, 8,122 cases of HZ were recorded, representing a mean incidence of 4.50 (95% confidence interval [CI]: 4.15-4.85) per 1,000 person-years (PY). The incidence increased with age, being lowest in adults 18-29 years (1.87 cases per 1,000 PY) and highest in adults 80-89 years (7.27 cases per 1,000 PY). PHN frequency was 50.85 cases per 1,000 HZ patients (95% CI: 37.31-64.39). The median duration of PHN was 981 days (interquartile range [IQR]: 487-1,718). Other complications included cutaneous (31.3 cases/1,000 HZ cases), ophthalmic (6.0 cases/1,000 HZ cases), and neurological (1.85 cases/1,000 HZ cases) complications. Recurrent HZ occurred in 4.25% of cases, with a median time to recurrence of 815 days (IQR: 308-1,890). Conclusion: These results illustrate the high burden of HZ and its complications in Argentina, highlighting the need for HZ prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.